These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 20358262)

  • 1. Analysis of individual drug use as a time-varying determinant of exposure in prospective population-based cohort studies.
    Stricker BH; Stijnen T
    Eur J Epidemiol; 2010 Apr; 25(4):245-51. PubMed ID: 20358262
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Performance of instrumental variable methods in cohort and nested case-control studies: a simulation study.
    Uddin MJ; Groenwold RH; de Boer A; Belitser SV; Roes KC; Hoes AW; Klungel OH
    Pharmacoepidemiol Drug Saf; 2014 Feb; 23(2):165-77. PubMed ID: 24306965
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Using fractional polynomials to model the effect of cumulative duration of exposure on outcomes: applications to cohort and nested case-control designs.
    Austin PC; Park-Wyllie LY; Juurlink DN
    Pharmacoepidemiol Drug Saf; 2014 Aug; 23(8):819-29. PubMed ID: 24664670
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immortal time bias in pharmaco-epidemiology.
    Suissa S
    Am J Epidemiol; 2008 Feb; 167(4):492-9. PubMed ID: 18056625
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A probabilistic bias analysis for misclassified categorical exposures, with application to oral anti-hyperglycaemic drugs.
    Arfè A; Nicotra F; Ghirardi A; Simonetti M; Lapi F; Sturkenboom M; Corrao G
    Pharmacoepidemiol Drug Saf; 2016 Dec; 25(12):1443-1450. PubMed ID: 27594547
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exposure-time-varying hazard function ratios in case-control studies of drug effects.
    Guess HA
    Pharmacoepidemiol Drug Saf; 2006 Feb; 15(2):81-92. PubMed ID: 16287211
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparison of estimators from self-controlled case series, case-crossover design, and sequence symmetry analysis for pharmacoepidemiological studies.
    Takeuchi Y; Shinozaki T; Matsuyama Y
    BMC Med Res Methodol; 2018 Jan; 18(1):4. PubMed ID: 29310575
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of Drug Exposure Definitions on Observed Associations in Pharmacoepidemiology Research.
    Eskin M; Eurich DT; Simpson SH
    J Popul Ther Clin Pharmacol; 2018 Mar; 25(1):e39-e52. PubMed ID: 29949683
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Methods for time-varying exposure related problems in pharmacoepidemiology: An overview.
    Pazzagli L; Linder M; Zhang M; Vago E; Stang P; Myers D; Andersen M; Bahmanyar S
    Pharmacoepidemiol Drug Saf; 2018 Feb; 27(2):148-160. PubMed ID: 29285840
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of long-term exposure to traffic-related air pollution on respiratory and cardiovascular mortality in the Netherlands: the NLCS-AIR study.
    Brunekreef B; Beelen R; Hoek G; Schouten L; Bausch-Goldbohm S; Fischer P; Armstrong B; Hughes E; Jerrett M; van den Brandt P
    Res Rep Health Eff Inst; 2009 Mar; (139):5-71; discussion 73-89. PubMed ID: 19554969
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The use of uncertain exposure-A method to define switching and add-on in pharmacoepidemiology.
    Pazzagli L; Linder M; Reutfors J; Brandt L
    Pharmacoepidemiol Drug Saf; 2022 Jan; 31(1):28-36. PubMed ID: 34558772
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A systematic review on the application of pharmacoepidemiology in assessing prescription drug-related adverse events in pediatrics.
    Luo X; Cappelleri JC; Frush K
    Curr Med Res Opin; 2007 May; 23(5):1015-24. PubMed ID: 17526119
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analytical approaches to minimizing immeasurable time bias in cohort studies.
    Oh IS; Baek YH; Jeong HE; Filion KB; Shin JY
    Int J Epidemiol; 2021 Jul; 50(3):987-999. PubMed ID: 33367629
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Flexible modeling of the cumulative effects of time-dependent exposures on the hazard.
    Sylvestre MP; Abrahamowicz M
    Stat Med; 2009 Nov; 28(27):3437-53. PubMed ID: 19708037
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Considerations for Pharmacoepidemiological Studies of Drug-Cancer Associations.
    Pottegård A; Friis S; Stürmer T; Hallas J; Bahmanyar S
    Basic Clin Pharmacol Toxicol; 2018 May; 122(5):451-459. PubMed ID: 29265740
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantifying bias reduction with fixed-duration versus all-available covariate assessment periods.
    Connolly JG; Schneeweiss S; Glynn RJ; Gagne JJ
    Pharmacoepidemiol Drug Saf; 2019 May; 28(5):665-670. PubMed ID: 30786103
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Re: The Quasi-cohort Approach in Pharmaco epidemiology: Upgrading the Nested Case-control.
    Tanaka S; Noma H
    Epidemiology; 2016 Jan; 27(1):e1. PubMed ID: 26426940
    [No Abstract]   [Full Text] [Related]  

  • 18. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bias in case-crossover studies of medications due to persistent use: A simulation study.
    Bykov K; Wang SV; Hallas J; Pottegård A; Maclure M; Gagne JJ
    Pharmacoepidemiol Drug Saf; 2020 Sep; 29(9):1079-1085. PubMed ID: 32548875
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immeasurable time bias due to hospitalization in medico-administrative databases: which impact for pharmacoepidemiological studies?
    Palmaro A; Boucherie Q; Dupouy J; Micallef J; Lapeyre-Mestre M
    Pharmacoepidemiol Drug Saf; 2017 May; 26(5):544-553. PubMed ID: 28266748
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.